The Receptor Interacting Serine/Threonine Protein Kinase 2 pipeline drugs market research report outlays comprehensive information on the Receptor Interacting Serine/Threonine Protein Kinase 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Receptor Interacting Serine/Threonine Protein Kinase 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Immunology, Gastrointestinal, Oncology, and Central Nervous System which include the indications Autoimmune Disorders, Unspecified Immunological Disorders, Ulcerative Colitis, Crohn’s Disease (Regional Enteritis), Unspecified Cancer, Multiple Sclerosis, and Encephalomyelitis. It also reviews key players involved in Receptor Interacting Serine/Threonine Protein Kinase 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Receptor Interacting Serine/Threonine Protein Kinase 2 pipeline targets constitutes close to seven molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, and Discovery stages are 1, 4, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Receptor Interacting Serine/Threonine Protein Kinase 2 overview
Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2), also known as RIP2, is a key signaling protein involved in the regulation of innate immune responses and inflammatory pathways. RIPK2 is a member of the RIP kinase family and plays a crucial role in mediating signals from various pattern recognition receptors (PRRs), such as NOD1 and NOD2, which are part of the NOD-like receptor (NLR) family. The activation of RIPK2 occurs in response to the detection of bacterial peptidoglycans by NOD1 and NOD2. Upon ligand binding, these receptors recruit RIPK2 to the site of bacterial infection. Activated RIPK2 then serves as a signaling hub, facilitating the activation of downstream pathways, including the NF-κB and MAPK signaling cascades. The activation of RIPK2 is also implicated in the modulation of autophagy. Aberrant activation or dysregulation of RIPK2 has been associated with inflammatory disorders and autoimmune diseases. In certain conditions, excessive RIPK2 activity can lead to chronic inflammation and tissue damage.
For a complete picture of Receptor Interacting Serine/Threonine Protein Kinase 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
